Abstract 344P
Background
Breast cancer imposes a significant regional and global health burden not only due to being the most prevalent malignancy in females in the Middle East and worldwide, but due to the associated substantial morbidity and mortality. Therefore, the determination of the epidemiological features of breast cancer in the Middle East is of prominent interest given the significant resultant burden associated with breast cancer as it enables for the efficient introduction of effective interventions.
Methods
Data on 20,046 female patients of different nationalities and residing in Jordan diagnosed with breast cancer during the period of 2000-2018 were obtained from the Jordan Cancer Registry. Consequently, comprehensive statistical analysis was performed to establish the epidemiological characteristics of breast cancer in Jordan, including the overall survival and crude incidence.
Results
A total of 20,046 female patients with a mean age of 51.5 ± 12.5 years old were included in the analysis. Only 6.54% of the enrolled patients were smokers at the time of diagnosis. Breast cancer was more commonly affecting the left breast, 46.9% of the patients, than the right breast, 43.5% of the patients, whereas 1.18% of the patients had breast cancer bilaterally. The upper outer quadrant of the breast was the most commonly reported site of tumour location. Moderately differentiated carcinoma was the most commonly encountered grade in 31.4% of the patients, whereas 28.9% had poorly differentiated carcinoma. Regional spread to the lymph nodes was observed in 19.0% of the sample and 13.1% of the patients had distant metastasis, while localized breast cancer was noted in 16.6% of the patients. A statistically significant increase in the crude incidence of breast cancer in females has been observed in Jordan over the 18 years period with a crude incidence estimated effect of 0.46 (P-value<0.001). The overall survival rate was determined to be 95.8%, 83.2%, and 62.8% at 1-year, 3-year, and 5-year interval, respectively.
Conclusions
Breast cancer in Jordan imposes a significant burden due to the significant increase in the crude incidence over the 18-year period, and thus mandating vigorous and vigilant screening and preventative measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Presenter: Andreas Trojan
Session: Poster session 03
372P - Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Presenter: Shona Nag
Session: Poster session 03
374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Presenter: Amrita Basu
Session: Poster session 03
375TiP - A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Presenter: Ludimila Cavalcante
Session: Poster session 03
388P - Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Presenter: Junji Tsurutani
Session: Poster session 03
391P - Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
Presenter: Andreas Bjerrum
Session: Poster session 03
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03